BIOYF (Biosyent) Cyclically Adjusted Revenue per Share: $1.77 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOYF Biosyent Inc BIOYF
98 GF Score
Price $10.38
GF Value $11.68
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Biosyent Cyclically Adjusted Revenue per Share?

Biosyent BIOYF +0.87% 98 Cyclically Adjusted Revenue per Share is $1.77 as of Mar. 2026. GuruFocus rates BIOYF with a GF Score™ of 98/100 and a GF Value™ of $11.68 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biosyent's adjusted revenue per share for the three months ended in Mar. 2026 was $0.874. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.77 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biosyent's average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biosyent was 40.40% per year. The lowest was 0.00% per year. And the median was 20.50% per year.

As of today (2026-07-14), Biosyent's current stock price is $10.38. Biosyent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.77. Biosyent's Cyclically Adjusted PS Ratio of today is 5.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 21.10. The lowest was 3.77. And the median was 6.21.


Biosyent  (OTCPK:BIOYF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biosyent's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.38/1.77
=5.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 21.10. The lowest was 3.77. And the median was 6.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biosyent Cyclically Adjusted Revenue per Share Related Terms


Biosyent Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biosyent's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent Cyclically Adjusted Revenue per Share Chart

Biosyent Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 1.20 1.40 1.45 1.76

Biosyent Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.65 1.70 1.76 1.77

BIOYF vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Cyclically Adjusted PS Ratio falls into.


BIOYF
98GF Score
Biosyent Inc BIOYF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosyent Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biosyent's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.874/132.2623*132.2623
=0.874

Current CPI (Mar. 2026) = 132.2623.

Biosyent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.233 102.002 0.302
201609 0.250 101.765 0.325
201612 0.246 101.449 0.321
201703 0.197 102.634 0.254
201706 0.292 103.029 0.375
201709 0.303 103.345 0.388
201712 0.312 103.345 0.399
201803 0.236 105.004 0.297
201806 0.309 105.557 0.387
201809 0.277 105.636 0.347
201812 0.303 105.399 0.380
201903 0.233 106.979 0.288
201906 0.276 107.690 0.339
201909 0.341 107.611 0.419
201912 0.311 107.769 0.382
202003 0.320 107.927 0.392
202006 0.270 108.401 0.329
202009 0.337 108.164 0.412
202012 0.348 108.559 0.424
202103 0.457 110.298 0.548
202106 0.462 111.720 0.547
202109 0.411 112.905 0.481
202112 0.443 113.774 0.515
202203 0.439 117.646 0.494
202206 0.410 120.806 0.449
202209 0.408 120.648 0.447
202212 0.445 120.964 0.487
202303 0.384 122.702 0.414
202306 0.488 124.203 0.520
202309 0.544 125.230 0.575
202312 0.514 125.072 0.544
202403 0.481 126.258 0.504
202406 0.553 127.522 0.574
202409 0.597 127.285 0.620
202412 0.527 127.364 0.547
202503 0.664 129.181 0.680
202506 0.648 129.892 0.660
202509 0.768 130.287 0.780
202512 0.609 130.366 0.618
202603 0.874 132.262 0.874

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.77 mean?
Biosyent (BIOYF) has a Cyclically Adjusted Revenue per Share of $1.77 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biosyent and its competitors.
Is Biosyent's Cyclically Adjusted Revenue per Share too high?
Biosyent's current Cyclically Adjusted Revenue per Share is $1.77. Overall, Biosyent has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Biosyent's Cyclically Adjusted Revenue per Share of $1.77 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biosyent and its competitors. Biosyent's current Cyclically Adjusted Revenue per Share is $1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (BIOYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.68, compared to a current price of $10.38 — trading 11.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.77. Biosyent's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biosyent (BIOYF), the current Cyclically Adjusted Revenue per Share is $1.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosyent (BIOYF) Overvalued in 2026?

Based on GuruFocus' analysis, Biosyent stock appears to be undervalued. The current stock price of $10.38 is trading 11.1% below its estimated GF Value™ of $11.68. GuruFocus considers Biosyent to be Modestly Undervalued.

Key valuation signals for BIOYF:

  • Cyclically Adjusted Revenue per Share: $1.77
  • GF Value™: $11.68 vs. price of $10.38 (11.1% below fair value)
  • GF Score™: 98/100 with 4 warning signs

No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biosyent Business Description

Other Exchanges RX:Canada
Address 2476 Argentia Road, Suite 402, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score

Get the complete analysis for BIOYF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.38
Price
$11.68
GF Value